Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
CARGO Therapeutics’ $281.3 Million Initial Public Offering
Alpine Immune Sciences’ $150 Million Common Stock Offering
Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the offering, and Latham & Watkins advised the underwriters. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced the...
Neumora Therapeutics’ $250.1 Million Initial Public Offering
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
Guardant Health’s Upsized Public Offering of Common Stock
Latham & Watkins Advises Guardant Health in Pricing of Upsized Public Offering of Common Stock. Guardant Health, Inc., a leading precision oncology company, has announced the pricing...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
Inspire Medical Systems’ $247.2 Million Common Stock Offering
Latham & Watkins represented Inspire in the offering, while Shearman & Sterling advised Goldman Sachs, as sole book-running manager. Inspire Medical Systems, Inc. (NYSE: INSP) executd an...
DigitalBridge Investment Management and IFM’s $11 Billion Take-Private Acquisition of Switch
Latham & Watkins advised the Special Committee of the Board of Directors of Switch, and Simpson Thacher & Bartlett advised DigitalBridge and IFM on the deal....
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in...
Minerva Surgical’s $75 Million Initial Public Offering
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB),...
Procept BioRobotics’ $163.9 Million Initial Public Offering
Latham & Watkins represented PROCEPT in the transaction. PROCEPT BioRobotics Corporation, a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology,...